Skip to main content
Fig. 5 | Cancer Imaging

Fig. 5

From: Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study

Fig. 5

Progression Free Survival (PFS) according to response in n = 32 relapse patients. A: RECIST v1.1 median PFS 7 months (responder, n = 25) versus 5 months (non responders, n = 7) p = 0.43 HR 0.7 95% CI 0.24 to 2.05. B: DECT (iodine concentration) median PFS 7 months (responders, n = 22) versus 4 months (non responders, n = 10) p =  0.0001, HR 0.1 95% CI 0.03 to 0.33. C: GCIG CA125 Median PFS 11 months (responders, n = 17) versus 4 months (non responders, n = 15) p =  0.0028, HR 0.23 95% CI 0.09 to 0.6

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us